Patients should seek medical evaluation for severe pain after injury, inability to bear weight, major swelling, deformity, numbness, weakness, fever, signs of infection, worsening abdominal pain, blood in stool, persistent vomiting, chest pain, shortness of breath, or neurological symptoms
Participants in the GLP-1 group were stratified by change in weight (weight loss of 10% or more, weight loss of less than 10% or weight gain)
In der wegweisenden Arbeit von Raun und Kollegen (1998) wurde es als das erste GHRP mit einer Selektivitt beschrieben, die der von GHRH nahekommt also GH-freisetzend, ohne Cortisol, Prolaktin oder ACTH nennenswert zu stimulieren
Totally agree with that
Vision loss claims: There is a growing number of reports linking GLP-1 drugs to non-arteritic anterior ischemic optic neuropathy (NAION), a condition that reduces blood flow to the optic nerve and can cause sudden, permanent vision loss